Abstract Purpose: We have previously reported that EPHB2 is overexpressed in gastric cancer; however, the expression profiles of its ligands, EFNB1 and EFNB2, are unknown. This study was designed to investigate the expression of EPHB2 and its ligands, EFNB1 and EFNB2, in human gastric cancer. Methods: Semi-quantitative RT-PCR using 32 P was performed on human gastric cancer tissues and corresponding normal tissues (29 gastric cancer patients). Results: EPHB2 was more highly expressed in tumor tissues than in normal tissues in 21 out of 29 (72.4%), in gastric cancer patients (P = 0.01); EFNB1 and EFNB2 were highly expressed in 21 out of 29 (72.4%) (P = 0.037) and 14 out of 29 (48.3%) patients, respectively. The overexpression of EPHB2 was frequently detected in both well-differentiated adenocarcinoma and poorly differentiated adenocarcinoma [10/13 (76.9%) and 9/14 (64.3%), respectively]. On the other hand, the overexpression of EFNB1 was more frequently detected in poorly differentiated adenocarcinoma than in well-differentiated adenocarcinoma [12/14 (85.7%) and 7/ 13 (53.8%), respectively. P =0.027]. Elevated levels of EPHB2 and EFNB1 were detected in substantial subsets of early gastric cancers. Genomic alterations to these three genes in gastric cancer specimens were either not found or rarely found except for several rare variations of EPHB2. Conclusions: These findings suggest that not only the expression of EPHB2, but the expression of its ligand EFNB1 may have some relation with the oncogenesis of gastric cancer.
Introduction
Receptor tyrosine kinases have been widely implicated in the generation and progression of common human tumors, and are often the products of transforming oncogenes (van der Geer et al. 1994) . The erythropoietinproducing hepatocellular (EPH) receptors represent the largest known family of receptor tyrosine kinases and are activated by interactions with cell-surface ligands, termed EFNs. The EPH family receptor kinases and their EFN ligands are well-known to be involved in fundamental developmental processes of the nervous system, including axon guidance (Tessier-Lavigne 1995) , axon fasciculation (Winslow et al. 1995) , neural crest cell migration (Wang and Anderson 1997) , acquisition of brain subregional identity (Lumsden and Krumlauf 1996) , and neuronal cell survival (Magal et al. 1996) . However, the activities of EPH and EFNs are not restricted to the neural system. Evidence suggests that some members of the EPH family and their ligands play important roles in angiogenesis and oncogenesis, where they influence cell adhesion, morphogenesis, capillary sprouting, and chemoattraction (Adams et al. 1999; Bohme et al. 1996; George et al. 1998; Mellitzer et al. 1999; Pandey et al. 1995) . Interestingly, reverse signaling from receptors to ligands is also known to be involved in cell-cell interactions and compartmentalization . EPH receptors have been classified into two subfamilies, EPHA and EPHB, according to their preference for either glycosylphosphatidylinositol (GPI)-anchored EFN-A ligands or transmembrane EFN-B ligands. Thus far, 14 vertebrate receptors and eight ligands have been identified. Previously, the overexpression of EPH family transcripts has been observed in melanomas, and carcinomas of the colon, lung, and liver in addition to gastric cancer (Easty et al. 1995; Kiyokawa et al. 1994; Maru et al. 1990 ). However, information on the expression of EPH receptor ligands, such as EFNB1 and EFNB2, in gastrointestinal tract tumors is sparse. We have previously reported that EPHB2 is expressed at higher levels in various tumors of epithelial origin, most frequently in gastric cancers, than in corresponding normal tissues [ Northern blot analysis, 12 out of 16 (75%) specimens] (Kiyokawa et al. 1994) . However, the expression profiles of the EFNB1 and EFNB2 ligands were not investigated because these ligands had not yet been isolated (Kiyokawa et al. 1994) . In this report, we examine the expression of EPHB2 and its ligands EFNB1, and EFNB2 in gastric cancer specimens using semi-quantitative RT-PCR analysis. In addition, we searched for genomic alterations to these genes in gastric cancer specimens to complement our expression study.
Materials and methods

Tissues
RT-PCR samples of human gastric cancer specimens and normal tissues were obtained from surgical resections performed at the Hamamatsu University School of Medicine. The tumor tissue samples were obtained from 29 gastric cancers. The clinicopathological characteristics of the 29 gastric cancer patients are shown in Table 1 . The specimens consisted of six early gastric cancers and 23 advanced gastric cancers. All of the samples were immediately frozen in liquid nitrogen and stored at -80°C until RNA preparation.
RNA Extraction and reverse transcription
Total cellular RNA was extracted from human tissues using the RNA extraction reagent, ISOGEN (Nippon Gene, Tokyo, Japan) according to the manufacturer's protocol. Single-stranded cDNA was prepared from the total RNA and 1 lg of oligo dT primer (Life Technologies, Rockvile, Md., USA) in a total volume of 20 ll containing Moloney murine leukemia virus reverse transcriptase (Life Technologies) and RNase inhibitor (Toyobo, Tokyo, Japan).
Semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis
The RT-PCR method used in this study was a modification of a previously described method (Sirotnak et al. 2000) . For the quantification of human EPHB2, EFNs, and b-actin mRNA by RT-PCR, the corresponding cDNA was diluted in water and mixed in a final volume of 20 ll with 0.625l mol/l of primer pairs, 1 U of Taq DNA polymerase, and 1 lCi of ( 32 P) dCTP. Nucleotide sequences for the PCR primers were synthesized according to published sequence information (Tang et al. 1999) . The primer sequences are as shown in Table 2 . The sizes of b-actin, EPHB2, EFNB1, and EFNB2 were 121 bp, 224 bp, 175 bp, and 161 bp, respectively. Amplification was performed in a DNA thermal cycler (PC-700, ASTEC, Fukuoka, Japan). For the human b-actin control, 30 cycles of denaturation were performed for 45 s at 94°C followed by primer annealing for 1 min at 59°C, polymerization for 1 min at 72°C, and final extension for 10 min at 72°C. For EPHB2 and EFNs, 35 cycles of denaturation were performed for 45 s at 94°C followed by primer annealing for 1 min at 59°C, polymerization for 1 min at 72°C, and final extension for 10 min at 72°C. Under these conditions, PCR was performed during the exponential phase of amplification for b-actin, EPHB2, and the EFNs (Fig. 1) . A negative control was added to exclude the possibility of DNA contamination in each reaction. The integrity of the RNA obtained from the clinical samples was confirmed by determining the presence of b-actin mRNA in the same samples. The PCR products were separated by electrophoresis on 6% polyacrylamide gels, which were then dried and subjected to autoradiography and image analysis (MacBAS; Fuji Film, Tokyo, Japan). All values of the RI (radio-isotope) count, including b-actin, were transformed into a logarithm, and we took the count of each RNA message to be proportional to that of b-actin. The expression of b-actin, EPHB2, EFNB1, and EFNB2 in gastric cancer specimens is shown in Fig. 2 . 
GCAAGTTCTGCTGGATCAAC AGGATGTTGTTCCCCGAATG Genomic analysis of EPHB2, EFNB1, and EFNB2
Genomic DNA was isolated from other subsets of gastric cancer and corresponding non-tumor tissues that had been stored at -80°C. The experimental protocol was approved by the ethical committee of Hamamatsu University School of Medicine. The EPHB2 primers for all 16 exons of the EPHB2 gene that were used in the PCR-SSCP analysis have been previously described (Oba et al. 2001) . The EFNB1 and EFNB2 primers used in the PCR-SSCP analysis are listed in Tables 3, 4 , and 5.
Statistical analysis
The statistical significance of associations between the expression of EPHB2 and its ligands, EFNB1 and EFNB2, in normal and tumor tissues was evaluated using the Wilcoxon signed-rank test, which is based on the rank of the differences between each pair of tissues in the observation. The results were considered to be significant when the P value was less than 0.05. The statistical significance of the expression of EPH/EFN in tumor tissues according to the clinical stages or the histological types were evaluated using the nonparametric 2-sample test (Wilcoxon test). The results were considered to be significant when the P value was less than 0.05.
Results
Expression of EPHB2, EFNB1, and EFNB2 in normal and human gastric cancer tumor tissues EPHB2 expression was elevated in tumor tissues, compared to normal tissues, in 21 out of 29 gastric cancer specimens (72.4%) (Fig. 3A) . EFNB1 and EFNB2 ligand expression was elevated in substantial subsets of the tumor tissues, compared to normal tissues, in 21 out of 29 (72.4%), and 14 out of 29 (48.3%) of the specimens, respectively (Fig. 3B,C ). EPHB2 and EFNB1 were significantly overexpressed in tumor tissues, compared to normal tissues (P=0.01 for EPHB2, P=0.037 for EFNB1). EPHB2 and EFNB1 were co-overexpressed in Fig. 1 . Expressions of EPH and b-actin in gastric cancer tissue and corresponding normal mucosa. In this experiment, the PCR program was set so that the exponential phase of amplification for b-actin, EPHB2, and EFNs are taken an amino acid substitution, the significance of which is unclear at this time, was also identified (data not shown). However, loss of heterozygosity (LOH) was not detected, unlike the situation in colon cancer (Oba et al. 2001) . No genomic alterations were found for EFNB1 or EFNB2.
Discussion
In this study, we used semi-quantitative RT-PCR analysis to evaluate the EPH/EFNs expression levels in 29 clinical samples obtained from patients with gastric cancer. Receptor tyrosine kinases and their ligands play a critical role in the regulation of cellular survival, proliferation, and differentiation (Schlessinger and Ullrich 1992) . Previously, the coexpression of the EPH-B subgroup and the EFN-B subgroup has been observed in small-cell lung carcinoma cell lines and tumors (Tang et al. 1999) . We also reported that EPHB2 is expressed at higher levels in various tumors of epithelial origin, compared to the expression levels in corresponding normal tissues; the highest frequency of overexpression occurred in gastric cancers, as observed by Northern Blot analysis (12 out of 16 specimens, 75%) (Kiyokawa et al. 1994 ). The expression profiles of the EFNB1 and EFNB2 ligands were not discussed at that time (Kiyokawa et al. 1994) , thus, this report is the first documentation of the status of EFNB1 and EFNB2 in gastric cancer. The cytoplasmic domains of the transmembrane ligands EFNB1 and EFNB2 have been shown to be phosphorylated on tyrosine residues after contact with their receptors, suggesting that the transmembrane ligands have a receptor-like intrinsic signaling potential (Bruckner et al. 1997) . The EFNB1 and EFNB2 ligands are 56% homologous and have very highly conserved intracellular domains (75% homology) . The striking conservation of the intracellular residues in the EFNB1 and EFNB2 ligands is intriguing and suggests a functional role for the C terminus of these molecules . The C-terminal valine residue may be critical for the potential production of a soluble form of EFNB1 . As is the case with other growth factors, possible genomic changes of these ligands in cancer were intriguing, but as shown here, significant genomic changes were not detected. Epigenetic changes such as promoter methylation in EFNs have not been detected so far (data, not shown).
We could also highlight the difference between EFNB1 and EFNB2 in terms of expression profile in gastric cancer. EFNB1 and EFNB2 are known to have different histological and physiological distributions during development. EFNB1 is historically the first ligand that has been shown to bind to the receptor EPHB2 (George et al. 1998) . Though another receptor EPHB4 has been shown to be specific for EFNB2, the EFNB2 ligand also binds and induces the subsequent auto-phosphorylation of the EPHB2 receptor Brambilla et al. 1996; Gale et al. 1996; Sakano et al. 1996) . On the other hand, EFNB2 did not produce a signal through EPHB2 in a cellular transformation assay, suggesting that EFNB1 may be the preferred EPHB2 ligand in vivo (Brambilla et al. 1996) . Actually, in the clinical settings described here, EFNB2 was not as frequently overexpressed in the gastric cancer specimens and does not seem to be related to the expression of its corresponding receptor.
The expression of ligands and receptors in tumor cells may down-regulate cell adhesion, thereby favoring the dissemination of metastases. Another line of investigation has found that the expression of EFNB1 in the vasculature (Pandey et al. 1995; Daniel et al. 1996) and EFNB2 in the bone marrow (Inada et al. 1997 ) may influence the targeting of metastatic cells expressing EPH receptors. EPH receptors share a common feature with receptor tyrosine kinases (Schlessinger and Ullrich 1992) . Upon EFN-binding, which is mediated by the EPH amino-terminal globular domain (Labrador et al. 1997) , the auto-phosphorylation of the receptor is induced. As EFNs are thought to be exclusively membrane-bound molecules that require membrane attachment or clustering for full functionality (Davis et al. 1994) , the EFN-EPH interactions may be restricted to direct cell-to-cell signaling events. Considering the biological background described above, frequent co-overexpression of EPHB2 and its ligand EFNB1 in our clinical cases may imply the considerable contribution of EPHB2-EFNB1 signaling to gastric carcinogenesis. In our series, the overexpression of EFNB1 seemed to increase as the clinical stage advanced, whereas that of EPHB2 did not (statistically not significant). Both EPHB2 and EFNB1 were overexpressed during the early stage of carcinogenesis.
In addition to the finding that EFNB1/EPHB2 overexpression is observed in the early stage of human gastric carcinogenesis, preferential overexpression of EFNB1 in the poorly differentiated category was noteworthy (P = 0.027); however, EPHB2 overexpression was prominent both in well-differentiated and poorly differentiated adenocarcinoma.
EPH receptors and EFNs exhibit a unique mode of signalling in that each molecule can function as both a ligand and a receptor capable of bidirectional signal transduction. Recent data suggests that the activation of reverse signaling after interactions with EPHB2 extracellular domains leads to clustering and tyrosine phosphorylation of the cytoplasmic tail of EFNB1 and the concomitant recruitment of Grb4 and its SH3-binding partners (Cowan and Henkemeyer 2001) . Alterations of these downstream molecules of EFNB1 in gastric cancer may be also intriguing. Further study is necessary to clarify the roles of the EPH-EFN family in oncogenesis. Our documentation may promote further investigation as to the mutual interactions of this receptor-ligand pair in oncogenesis of human stomach (Cowan and Henkemeyer 2001) .
